India approves Moderna's Covid-19 vaccine for emergency use
The vast nation of 1.3 billion people was hit by a massive spike in coronavirus cases in April and May that pushed the healthcare system to breaking point.
Moderna's shot is the fourth to be approved by New Delhi after Oxford-AstraZeneca's Covishield and Covaxin -- which was developed by Indian firm Bharat Biotech -- and Russia's Sputnik V.
"I am pleased to inform that an application received from Moderna through an Indian partner of theirs, Cipla, has been granted EUA (Emergency Use Authorisation)," Vinod K. Paul, a member of government advisory body NITI Aayog, said at a health ministry briefing.
Paul added that the approval would pave the way for other foreign-made vaccines to be imported into India, with efforts to get Pfizer and Johnson & Johnson jabs ongoing.
A small number of Sputnik V shots were imported into India after the drug was approved in mid-April, but the majority are expected to be manufactured within the country, like Covishield and Covaxin.
India said two months ago that it would fast-track the approval of vaccines manufactured outside the country that have already been granted emergency use authorisation by major regulators such as the US Food and Drug Administration.
The government has been under pressure to speed up its flagging inoculation drive by allowing the import of foreign-made shots such as mRNA vaccines Pfizer and Moderna.
"We should have as many vaccines and alternatives as possible," said Dr Rakesh Mishra, the former director of research body the Centre for Cellular Molecular Biology, who welcomed the approval.
Anant Bhan, a senior researcher in health and bioethics, said that the Moderna vaccine -- which needs to be stored at minus 20 degrees Celsius (minus four Fahrenheit) -- was unlikely to be for mass use due to its cold-chain requirements and higher price tag.
"It's primarily going to be used in the private health sector largely present in the cities. There, they can manage and build to meet some of its storage requirements," Bhan told AFP.
"It is a welcome decision but the question is also what it means in terms of access, number of doses and price point. We will have to wait and watch for that."
More than 329 million doses have been administered since the mass coronavirus vaccination programme kicked off in mid-January.
But just six percent of India's adult population -- or 57 million people -- have received both doses of a two-shot regime.
India has the world's second-highest number of infections, with more than 30 million cases and nearly 398,000 deaths.